Skip to main content
SpringerLink
Log in

Diurétiques et vasodilatateurs

  • Chapter
Book cover L’insuffisance cardiaque aiguë

Part of the book series: Le point sur... ((POINT))

  • 473 Accesses

Abstrait

Le but du traitement ďune insuffisance cardiaque aiguë est ďaméliorer rapidement les symptômes et le profil hémodynamique du patient. Très peu ďétudes sérieuses de morbimortalité (contre placebo) ont été réalisées avec des diurétiques, des dérivés nitrés ou autres vasodilatateurs dans ľinsuffisance cardiaque aiguë. Or ľhistoire du traitement de ľinsuffisance cardiaque chronique nous a appris qu’il n’y avait pas de relation entre amélioration hémodynamique et amélioration du pronostic. Néanmoins, on voit mal comment il est possible ďaméliorer le devenir ďun patient en insuffisance cardiaque aiguë sans corriger rapidement son hémodynamique. Les données dont nous disposons sur les nitrés et les diurétiques portent donc essentiellement sur les effets hémodynamiques et les symptômes, et c’est dans cette optique ďune correction rapide de certains «profils hémodynamiques« ďinsuffisance cardiaque aiguë qu’est abordé ce chapitre.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Stevenson LW (1991) Tailored therapy before transplantation for treatment of advanced heart failure: effective use of vasodilators and diuretics. J Heart Lung Transplant. 10: 468–76

    PubMed  CAS  Google Scholar 

  2. Brater DG (1998) Diuretic therapy. New Engl J Med. 339: 387–395

    Article  PubMed  CAS  Google Scholar 

  3. Shankar SS and Brater DG (2003) Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 284: F11–F21

    PubMed  CAS  Google Scholar 

  4. Dickshit K, Vyden J, Forrester J et al. (1973) Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after myocardial infarction. N Engl J Med. 288: 1087–90

    Google Scholar 

  5. Pikkers P, Dormans TPJ, Russel FGM et al. (1997) Direct vascular effects of furosemide in humans. Circulation. 96: 1847–52

    Google Scholar 

  6. Dormans TP, Van Meyel JJ, Gerlag PG et al. (1996) Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol. 28: 376–82

    Article  PubMed  CAS  Google Scholar 

  7. Aaser E, Gullestad L, Tollofsrud S et al. (1997) Effect of bolus injection versus continuous infusion of furosemide on diuresis and neurohormonal activation in patients with severe congestive heart failure. Scand J Clin Lab Invest. 57: 361–7

    Article  PubMed  CAS  Google Scholar 

  8. Earl G, Davenport J, Narula J (2003) Furosemide challenge in patients with heart failure and adverse reactions to sulfa-containing diuretics. Annals Med Intern. 138: 358

    Google Scholar 

  9. Northridge D (1996) Furosemide or nitrates for acute heart failure. Lancet. 347: 667–8

    Article  PubMed  CAS  Google Scholar 

  10. Cotter G, Metzkor E, Kaluski E et al. (1998) Randomised trial of high-dose isosorbide dinitrate plus low-dose furosemide versus high-dose furosemide plus low-dose isosorbide dinitrate in severe pulmonary œdema. Lancet. 351: 389–93

    Article  PubMed  CAS  Google Scholar 

  11. Vargo DL, Kramer WG, Black PK et al. (1995) Bioavailability, pharmacokinetics and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 57: 601–9

    Article  PubMed  CAS  Google Scholar 

  12. Loon NR, Wicox CS, Unwin RJ (1989) Mechanism of imlaired natriuretic presponse to furosemide during prolonged therapy. Kidney Int. 36: 682–9

    Article  PubMed  CAS  Google Scholar 

  13. Ellison DH, Velazquez H, Wright FS (1989) Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 83: 1113–26

    Google Scholar 

  14. Oster JR, Epstein M, Smoller S (1983) Combined therapy with thiazide-type and loop diuretic agents for resistant sodium retention. Ann Intern Med. 99: 405–6

    PubMed  CAS  Google Scholar 

  15. Ellison DH (1991) The physiologic basis of diuretic synergism/ its role in treating diuretic resistance. Ann Intern Med. 114: 886–94

    PubMed  CAS  Google Scholar 

  16. Van Vliet AA, Donker AJM, Nauta JJP, Verheugt FWA (1993) Spironolactone in congestive heart failure refractory to high-dose loop diuretic and low-dose angiotensin-converting enzyme inhibitor. Am J Cardiol. 71: 21A–28A

    Article  PubMed  Google Scholar 

  17. Wilcox CS

    Google Scholar 

  18. Weinfeld MS, Chertow GM, Stevenson LW (1999) Aggravated renal dysfunction during intensive therapy for advanced chronic heart failure. Am Heart J. 138: 285–90

    Article  PubMed  CAS  Google Scholar 

  19. Butler J, Forman DE, Abraham WT, et al. (2004) Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J. 147: 331–8

    Article  PubMed  Google Scholar 

  20. Licata G, Di Pasquale P, Parrinello G et al. (2003) Effects of high-dose furosemide and small-volume hypertonic saline soultion infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure. Am Heart J. 145: 459–66

    Article  PubMed  CAS  Google Scholar 

  21. Denton MD, Chertow GM, Brady HR (1996) «Renal-dose« dopamine for the treatment of acute heart renal failure: scientific rationale, experimental studies and clinical trials. Kidney Int. 50: 4–14

    Article  PubMed  CAS  Google Scholar 

  22. Vargo DL, Brater DC, Rudy DW, Swan SK (1996) Dopamine does not enhance furosemide-induced natriuresis in patients with congestive heart failure. J Am Soc Nephrol. 7: 1032–7

    PubMed  CAS  Google Scholar 

  23. Bart BA, Boyle A, Bank AJ et al. (2005) Ultrafiltration versus usual care for hospitalized patients with heart failure. J Am Coll cardiol. 46: 2043–6

    Article  PubMed  Google Scholar 

  24. Costanzo MR, Satzberg M, O’Sullivan J, Sobotka P (2005) Early ultrafiltration in patients with decompensated heart failure and diuretic resistance. J Am Coll Cardiol. 46: 2047–51

    Article  PubMed  Google Scholar 

  25. Lee CR, Watkins ML, Patterson JH et al. Vasopressin: a new target for the treatment of heart failure. Am Heart J 2003; 146: 9–18

    Article  PubMed  CAS  Google Scholar 

  26. Gheorghiade M Gattis WA, O’Connor CM et al. (2004) Effects of tovalptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA. 291: 1963–71

    Article  PubMed  CAS  Google Scholar 

  27. Jain P, Massie BM, Gattis WA et al. (2003) Current medical treatment for the exacerbation of chronic heart failure resulting in hospitalization. Am Heart J. 145: S3–S17

    Article  PubMed  Google Scholar 

  28. Nieminen MS, Bohm M, Cowie MR et al. (2005) Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology. Eur Heart J. 26: 384–416

    Article  PubMed  Google Scholar 

  29. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. (1987) 16: 1429–35

    Google Scholar 

  30. Pfeffer MA, McMurray JJ, Velazquez EJ et al. (2003) Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 349: 1893–906

    Article  PubMed  CAS  Google Scholar 

  31. Cataliotti A, Boerrigter G, Costello-Boerrigter LC, et al. (2004) Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure. Circulation. 109: 1680–5

    Article  PubMed  CAS  Google Scholar 

  32. Mills RM, LeJemtel TH, Horton DP et al. (1999) Sustained hemodynamic effects of an infusion of nesiritide (human b-type natriuretic peptide) in heart failure: a randomized, double-blind, placebo-controlled clinical trial. Natrecor Study Group. J Am Coll Cardiol. 34: 155–62

    Article  PubMed  CAS  Google Scholar 

  33. Colucci WS, Elkayam U, Horton DP et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med. 343: 246–53

    Article  PubMed  CAS  Google Scholar 

  34. Publication Committee for the VMAC Investigators (2002) Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure. A randomized trial. JAMA. 287: 1531–40

    Article  Google Scholar 

  35. Teerlink JR, McMurray JJ, Bourge RC et al. (2005) VERITAS Investigators. Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS). Am Heart J. 150: 46–53

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Service de cardiologie, Hôpital Lariboisière, 2, rue Ambroise Paré, 75010, Paris

    D. Logeart

Authors
  1. D. Logeart
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag France

About this chapter

Cite this chapter

Logeart, D. (2006). Diurétiques et vasodilatateurs. In: L’insuffisance cardiaque aiguë. Le point sur.... Springer, Paris. https://doi.org/10.1007/978-2-287-34066-6_13

Download citation

  • DOI: https://doi.org/10.1007/978-2-287-34066-6_13

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-287-34065-9

  • Online ISBN: 978-2-287-34066-6

Publish with us

Policies and ethics

Search

Navigation